Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$1.7M |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$108M |
 |
Editas MedicineEDIT |
-$17M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| O'Day Daniel Patrick | Jun 30, 2025 | Sell | 9,400 | $110.4038 | $1M |
| O'Day Daniel Patrick | Jun 30, 2025 | Sell | 600 | $111.1467 | $67,000 |
| Dickinson Andrew D | Jun 16, 2025 | Sell | 2,500 | $110.17 | $280,000 |
| Mercier Johanna | Jun 16, 2025 | Sell | 3,000 | $110.17 | $330,000 |
| O'Day Daniel Patrick | May 30, 2025 | Sell | 6,416 | $110.1148 | $710,000 |
| O'Day Daniel Patrick | May 30, 2025 | Sell | 3,584 | $110.9643 | $400,000 |
| Mercier Johanna | May 22, 2025 | Sell | 12,500 | $107.5231 | $1.3M |
| Mercier Johanna | May 22, 2025 | Sell | 3,000 | $107.5212 | $320,000 |
| Dickinson Andrew D | May 15, 2025 | Sell | 2,500 | $99.82 | $250,000 |
| Dickinson Andrew D | Apr 15, 2025 | Sell | 2,500 | $106.4 | $270,000 |
| Dickinson Andrew D | Mar 17, 2025 | Sell | 2,500 | $110.53 | $280,000 |
| Dickinson Andrew D | Mar 10, 2025 | Sell | 13,013 | $118.5011 | $1.5M |
| Dickinson Andrew D | Mar 10, 2025 | Sell | 4,916 | $117.2988 | $580,000 |
| Dickinson Andrew D | Feb 18, 2025 | Sell | 2,500 | $104.09 | $260,000 |
| Dickinson Andrew D | Feb 12, 2025 | Sell | 137,676 | $102.22 | $14M |
| Dickinson Andrew D | Jan 31, 2025 | Sell | 142,180 | $97.22 | $14M |
| Dickinson Andrew D | Jan 15, 2025 | Sell | 2,500 | $91.35 | $230,000 |
| Dickinson Andrew D | Dec 16, 2024 | Sell | 8,500 | $91.96 | $780,000 |
| Dickinson Andrew D | Nov 29, 2024 | Sell | 127,930 | $92.7626 | $12M |
| Dickinson Andrew D | Nov 29, 2024 | Sell | 120,715 | $92.7652 | $11M |
| Parsey Merdad | Nov 27, 2024 | Sell | 88,119 | $92 | $8.1M |
| Parsey Merdad | Nov 27, 2024 | Sell | 57,294 | $91.7949 | $5.3M |
| Parsey Merdad | Nov 27, 2024 | Sell | 10,399 | $92 | $960,000 |
| Parsey Merdad | Nov 27, 2024 | Sell | 5,200 | $91.8041 | $480,000 |
| Parsey Merdad | Nov 27, 2024 | Sell | 3,199 | $91.8034 | $290,000 |
| Bluestone Jeffrey | Nov 26, 2024 | Sell | 6,788 | $91.3901 | $620,000 |
| Parsey Merdad | Nov 6, 2024 | Sell | 20,590 | $91.5 | $1.9M |
| Mercier Johanna | Nov 6, 2024 | Sell | 5,000 | $91.28 | $460,000 |
| Parsey Merdad | Nov 6, 2024 | Sell | 5,000 | $91.5 | $460,000 |
| Parsey Merdad | Oct 1, 2024 | Sell | 2,000 | $83.83 | $170,000 |
| Parsey Merdad | Sep 12, 2024 | Sell | 21,246 | $84.5 | $1.8M |
| Mercier Johanna | Sep 12, 2024 | Sell | 15,925 | $84.23 | $1.3M |
| Mercier Johanna | Sep 12, 2024 | Sell | 13,432 | $83.25 | $1.1M |
| Mercier Johanna | Aug 28, 2024 | Sell | 9,513 | $78.03 | $740,000 |
| Mercier Johanna | Aug 13, 2024 | Sell | 5,490 | $73.98 | $410,000 |
| Parsey Merdad | Jul 1, 2024 | Sell | 2,000 | $68.63 | $140,000 |
| Parsey Merdad | Apr 1, 2024 | Sell | 2,000 | $72.96 | $150,000 |
| Parsey Merdad | Feb 29, 2024 | Sell | 8,230 | $72.7368 | $600,000 |
| Parsey Merdad | Feb 28, 2024 | Sell | 2,000 | $73.18 | $150,000 |
| Dickinson Andrew D | Jan 16, 2024 | Sell | 5,000 | $85.78 | $430,000 |
| Mercier Johanna | Jan 9, 2024 | Sell | 8,242 | $85.23 | $700,000 |
| Dickinson Andrew D | Oct 17, 2023 | Sell | 5,000 | $80.0034 | $400,000 |
| Parsey Merdad | Sep 12, 2023 | Sell | 1,501 | $76.99 | $120,000 |
| Dickinson Andrew D | Jul 20, 2023 | Sell | 5,000 | $80 | $400,000 |
What's the latest insider transaction for Gilead Sciences?
The most recent insider transaction for Gilead Sciences was conducted by O'Day Daniel Patrick, who sold 9,400 shares on June 30, 2025 at a price of $110.40 per share.
Which insider has sold the most GILD stock over the last two years?
Dickinson Andrew D has sold the most GILD stock in the last 2 years, with a total value of $57M.
What is the total value of insider transactions for Gilead Sciences (GILD) in the last 2 years?
The total value of insider transactions for Gilead Sciences in the last 2 years is negative, amounting to -$87M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Gilead Sciences' market confidence?
Over the last 2 years, insider transactions for Gilead Sciences have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
